Abstract B7-H3 (CD276), a member of the B7 family of proteins, is a key player in cancer
progression. This immune checkpoint molecule is selectively expressed in both tumor cells …

Current therapies against cancer utilize the patient's immune system for tumor eradication.
However, tumor cells can evade immune surveillance of CD8+ T and/or natural killer (NK) …

Glioblastoma (GBM) remains one of the most malignant primary tumors in adults, with a 5-
year survival rate less than 10% because of lacking effective treatment. Here, we aimed to …

B7H3 (also known as CD276, an immune checkpoint molecule) is aberrantly overexpressed
in many types of cancer, and such upregulation is generally associated with a poor clinical …

Recent studies have shown that circulating microRNAs are potential biomarkers for various
types of malignancies. The aim of this study was to investigate the feasibility of using serum …

Background Basal-like constitutes an important molecular subtype of breast cancer
characterised by an aggressive behaviour and a limited therapy response. The outcome of …

Substantial evolution in cancer therapy has been witnessed lately, steering mainly towards
immunotherapeutic approaches, replacing or in combination with classical therapies …

Novel, non-invasive biomarkers to diagnose breast cancer with high sensitivity and
specificity are greatly desired. Circulating microRNAs (miRNAs) show potential for breast …

Targeting the anti-tumor immune response via the B7 family of immune-regulatory
checkpoint proteins has revolutionized cancer treatment and resulted in punctuated …

Cancer immunotherapy represents a promising new era in cancer management due to the
relatively high safety margins and selectivity, compared to the classical cancer …